A health-policy news outlet reported this week that a single 79-year-old man was granted access to the investigational obesity drug retatrutide through the US Food and Drug Administration’s compassionate-use programme in April, drawing immediate attention because the patient’s age and profile matched those of President Donald Trump. The White House, after initially deflecting queries to the Department of Health and Human Services, issued an aggressive denial. Spokesman Kush Desai called the report “baseless speculation” and said the application “was not for the President,” while communications director Steven Cheung insulted the reporter. The journalist stated she had asked the White House, HHS and the FDA multiple times whether Trump was the patient and received no direct answer before publication.

Retatrutide, manufactured by Eli Lilly, is a next-generation triple-hormone-receptor agonist (GLP-1, GIP, glucagon) still in phase 3 clinical trials. The TRIUMPH-1 study, which enrolled 2,339 adults with obesity or overweight and comorbidities but without diabetes, showed an average weight reduction of 28.3% at the highest dose after 80 weeks—results approaching those of bariatric surgery. The compassionate-use request, submitted by a senior clinician at the National Institutes of Health, cited refractory obesity accompanied by obstructive sleep apnea and pulmonary hypertension, a condition that can be life-threatening. STAT, the outlet that broke the story, interviewed 18 bioethics specialists and obesity clinicians who described single-patient access for obesity under compassionate use as unusual; such programmes are typically reserved for immediately life-threatening conditions or conducted through larger patient groups.

Viewed from Washington, the episode intensifies scrutiny of the president’s health. Trump turned 80 this month, his disclosed weight rose to 238 pounds in his latest physical—a 14-pound increase since April 2025, nearing the clinical obesity threshold—and he has been photographed with swollen ankles and bruises on his hands. He previously received early access to Regeneron’s antibody cocktail when he contracted Covid-19 in 2020. The White House referred reporters to a May medical memo that declared Trump in “excellent health,” but that document contains no mention of sleep apnea or pulmonary hypertension. The denial was forceful, yet the initial refusal by multiple agencies to address the question directly has left the patient’s identity unconfirmed.

From a pharmaceutical perspective, Eli Lilly is preparing to launch retatrutide in Europe and the United Kingdom by late 2026 or early 2027, targeting direct-pay markets while pursuing public reimbursement where feasible. Those plans are complicated by the Trump administration’s “most favoured nation” drug-pricing policy, which seeks to tie US prices to those paid in other high-income countries. The drug’s regulatory submission remains pending; if approved, it would represent a significant pharmacological advance in obesity treatment. The next factual milestone is the completion of regulatory review, while the unresolved question of the compassionate-use patient’s identity continues to generate political and media attention.